Steris acquires Synergy Health, a UK-based outsourcing company focused on sterilization, for &1.9 billion USD.
Steris offered to acquire Synergy Health for $1.9 billion in cash and stocks. Steris, a company specializing in infection prevention, contamination control, surgical, and critical care technology, will benefit from the UK-based Synergy Health, specializing in outsourced sterilization services. In fiscal 2014, Synergy generated approximately $604 million in revenue and approximately $161 million in adjusted earnings before EBITDA.
Upon closing, expected in March 2015 according to a press release, the combined business will have approximately $2.6 billion in annual revenue. The acquisition will save the new company approximately $30 million annually in pre-tax cost savings due to a lowered tax rate. Similar to many mergers and acquisitions in the past year that have been dependent upon tax inversion, Steris will see a lowered tax rate of 25%, as opposed to the US corporate income tax rate of 35%, when combined with the UK company.
Source: Steris
Navigating Annex 1 for Early Phase Sterile Fill Finish in Clinical Supplies
November 21st 2024Stay compliant with Annex 1 for early phase sterile fill finish processes. Discover how to implement robust contamination control strategies, integrate isolator technology, and conduct integrity testing to meet stringent European Union standards. The guide provides a comprehensive look at key elements such as PUPSIT, critical zone controls, and monitoring and training for aseptic processes.
Why is the PDA Pharmaceutical Microbiology Conference the Hottest Ticket in the Industry?
October 10th 2024Get a glimpse of the power and popularity behind the PDA Pharmaceutical Microbiology Conference from two planning committee members, Julia Marre, PhD (Associate Director, Scientific and Regulatory Affairs at Pocket Naloxone Corp) and Dawn Watson (Executive Director, Global Micro Quality and Sterility Assurance at Merck). This candid conversation reveals why this industry event is so influential…and always sold out! The speakers discuss what makes the PDA Pharmaceutical Microbiology Conference so vital to industry professionals, as well as how to become a part of this dynamic professional community.
Ensuring Quality from the Start: Raw Materials Testing Support
November 21st 2024Raw Materials are the foundation of every biopharma product. Our ultimate guide highlights how our testing support can help you establish purity, identity, and quality standards, ensuring a smooth manufacturing process and adherence to regulatory requirements.
Ensure the Safety of Allogeneic Therapies with Advanced qPCR Testing
November 21st 2024Elevate your viral screening with Eurofins BioPharma Product Testing’s qPCR- based assays. Our advanced testing goes beyond standard screenings to detect even dormant and hard-to-detect pathogens, ensuring comprehensive safety in every stage of the allogeneic therapy pipeline. Protect your products – and your patients- with industry-leading sensitivity and specificity.